Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Would be nice to see a little positive movement today as they are at Virtual Conference.
I think impatience is a factor for all in most all aspects of life these days. But the FDA backlog is real and quite significant. Just gives us more time to accumulate on weakness.
I expect the Covid excuse is running out of steam….
COVID shutdowns have really stymied there efforts. I believe we should hear about some marketing efforts in the UK soon.
i dont think they are trying to go alone . I believe they are waiting for a partnership once they get the 510k.
Are they actually using the product and making sales yet in Europe? I remember they received the CE Mark back in early 2020 and don't recall seeing updates on commercilization and sales.
FDA- in researching how the FDA is doing with processing medical device applications, it is clear that they are very delayed due to COVID and it will take them time to catch up. This likely explains why there hasn’t been news in the timeline expected. This isn’t bad news. Patience is required. Still a green light in Europe. And that approval bodes well for a probable FDA approval
True not dissimilar from the overall market with a 60% below their 40-50DMA.
We're getting beaten up over here... $2 seemed to be a resistance level and now it's broken through.
I would expect we will on the 2nd qtr CC.
Anyway to find out how the partnerships with the universities are going? Surprised we haven't gotten any updates there.
After the FDA imo but we are still waiting on that.
Where’s that BO??
My gawd I can't wait for this to pop. Fingers crossed for some great news coming down the pike.
Did you participate in any of the financing's in 2019 or earlier? If so you may be one of the last that have not converted your warrants to shares.
I would reach out to David Wells and get those converted to shares; David Wells
Chief Financial Officer
(734) 997-0464
Thank you for your assistance on my previous question.
I'm seeking help again. I own some NDRAW warrants. During the last few years, I've been inactive because of medical problems. I now discover that sometime in the interim, I accumulated some NWDVW warrants My brokerage statement says they are worth 2 cents on lessthan 100 warrants and that my loss on the gain area on the website amounts to many thousands of dollars.
Any clarification you can provide would be greatly appreciated before I try to clarify the situation with my online broker. Especially any website with information. I really have no idea what/s going on here.
TIA
d
v
w
Correction 2022
Expire on May on 2020??
They expire in May of 2020 exercise price is approx $6.25 not sure of the exact number could be $6.20.
I'm seeking information about the warrants. nDRAW
I own some warrants from a few years ago. I had medical problems for about 1 1/2 years and am back trying to get into problems in my portfolio.
I have a great deal of trouble with the NDRA website.
Thanks in advamce fpr amy website or source of information about these warrants outstanding ...anything about their term length, expiration dates, or assistance of any type.
TIA
I watched but saw nothing….what did I miss??
Feel like NDRA has always been pretty active pre & post market and I've been a holder for 4 years or so. What are you inferring when you saw watch it pre & post?
Watch for action in the pre and post markets.
$NDRA/$NDRAW
Good for you. I’m with the rest of the world and will wait until until they can independently prove that it works.
we all have are opinion on when to buy. I am 2x here so I am happy.
dnd, that is well and good, but what one or two institutions do doesn’t mean much. Institutional ownership has been below 9% for the last five years, so they are not buying the story yet. I think waiting for measurable validation is prudent. They will be plenty of time to buy after that.
Vanguard bought 1.5M last qtr along with several other big purchases. One big seller who took a quick 3X from the offering in December.
Only 9% institutional ownership. Should be much, much higher if they believed..
lots of cash on hand.
no dilution needed in the next 12 months .
510k approval should be any day.
What’s everyone’s takeaway from the recent quarterly releases today?
Nice scoooooooop
Got my long awaited fill at $2.05 today. Now ready for the next move up.
Downward pressure today which is interesting given how the NASDAQ is taking off?! Just found this article from 3/31 as well:
https://pennystocks.com/featured/2021/03/31/4-penny-stocks-to-watch-before-look-blue-chips/
Awesome, love it!
Review the transcript from the 3/25. After I reviewed it I would say the answer to your question is NO.
Do they need data from the recent university partnership studies in order to obtain FDA approval?
I am FDA approval anyday, more drug partnerships, more patents, and sales. Double digits are coming.
Looking at the chart you could be right if we get one of those tails like we have seen twice before.
I think $2.10 is rock bottom
I want to get some more on the low 2s too
Call me greedy but I'm hoping for a pullback near 2 bucks
Huge endorsement & derisking event for NDRA & their TAEUS technology.
Hepion Pharma commits to using TAEUS in their critical Phase 2b NASH study even though TAEUS has not received FDA 510k Clearance yet??? Unprecedented IMO. This is strong evidence of just large the market for TAEUS will be...
Consider the opinion of someone who is not long NDRA but has done his due diligence. In fact, he is the CEO of another company. And he is bullish on TAEUS:
"Hepion Pharma is excited to incorporate ENDRA's technology into screening for our Phase 2b study of CRV431, which targets non-alcoholic steatohepatitis (NASH) and other liver diseases," said Hepion's CEO Dr. Robert Foster."
"... there is enormous potential value in capturing data on the degree of hepatic steatosis and other biomarkers to refine our understanding of systemic variables associated with NAFLD-NASH. We believe ENDRA's TAEUS system is uniquely designed to accomplish this task for us."
http://investors.endrainc.com/prviewer/release_only/id/4662746
Followers
|
52
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1262
|
Created
|
10/24/18
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |